What does qarziba — total revenues and income mean?

Represents the total financial inflows generated by a specific product or business segment, including royalties, milestone payments, and licensing fees. This metric serves as a primary indicator of the commercial success and market adoption of the asset within the company's portfolio.

Ligand Pharmaceuticals (LGND) Qarziba — Total revenues and income

Screener

Other product segments

Filspari

$13.57M+106%

Captisol

$7.98M—

Kyprolis

$7.04M—

Evomela

$5.94M-31.5%

Rylaze

$3.81M+3.7%

Ohtuvayre

$3.55M—

Ohtuvayre inventors

$3.29M—

Contract revenue

$2.68M—

Other

$2.59M—

Capvaxive

$2.32M—

Teriparatide injection

$2.03M+19.2%

Vaxneuvance

$1.35M-48.9%

Similar metrics at other companies

PTH

PTHSLicense and collaboration revenues — Total Revenue

$241K—

QTRXCollaboration and license revenue — Total revenues

$560K-27.4%

QTRXService and other revenue — Total revenues

$10.38M+17.6%

SNDAResident revenue — Total revenues

$108.43M+36.8%

ASSTOther revenue — Total revenues

$43K+514%

ESP

ESPRCollaboration revenue — Total Revenues

$36.71M+22.0%

Other financials

Income statement

See full

Revenue$63.7M+33.7%

Operating income$8.6M+1.7%

Net income$48.5M+901%

EPS (diluted)$2.22+825%

Balance sheet

See full

Cash & equivalents$1.0B+1,388%

Total debt$1.1B+19,605%

Total equity$967.5M+16.9%

Total assets$2.2B+130%

Cash flow

See full

Operating cash flow$24.0M+52.0%

CapEx$26.0K-87.9%

Free cash flow$24.0M+53.9%

Valuation

See full

Market cap$6.02B+119%

Enterprise value$6.14B+129%

P/E30.5×—

P/S20.7×+6.1×

Profitability

See full

Gross margin91.9%—

Operating margin32.6%+24.0pp

Net margin67.9%+49.4pp

FCF margin45.2%+16.7pp

Returns & leverage

See full

Return on equity22%+16.9pp

Debt / equity1.2×+1.2×

Current ratio31.2×+25.7×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.

Filed: Aug 7, 2026, 4:06 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0000886163-26-000044

Line item	Three months ended / June 30, 2026	Three months ended / June 30, 2025	Six months ended / June 30, 2026	Six months ended / June 30, 2025
Teriparatide injection	1,470	2,298	2,791	3,489
Other	4,269	2,564	8,030	6,235
Revenue from intangible royalty assets	37,362	30,084	70,293	51,671
Qarziba	6,150	5,885	12,449	11,327
Ohtuvayre inventors	3,294	—	6,341	—
Other	1,226	428	1,907	888
Income from financial royalty assets	10,670	6,313	20,697	12,215
Total royalties	48,032	36,397	90,990	63,886

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Ligand Pharmaceuticals's qarziba — total revenues and income?: Ligand Pharmaceuticals (LGND) reported qarziba — total revenues and income of $6.15M in Q2 2026.
How has Ligand Pharmaceuticals's qarziba — total revenues and income changed year-over-year?: Ligand Pharmaceuticals's qarziba — total revenues and income increased by 4.5% year-over-year, from $5.89M to $6.15M.
What does qarziba — total revenues and income mean?: Represents the total financial inflows generated by a specific product or business segment, including royalties, milestone payments, and licensing fees. This metric serves as a primary indicator of the commercial success and market adoption of the asset within the company's portfolio.